Anatomical and functional brain variables associated with clozapine response in treatment-resistant schizophrenia

Clozapine alleviates the symptoms of a significant proportion of treatment-resistant schizophrenic patients. Previous studies suggest that the response to clozapine may be associated with prefrontal and temporal anatomy as well as with prefrontal, basal ganglia and thalamic metabolism. A sample of 25 treatment-resistant (TR) schizophrenic patients underwent magnetic resonance imaging (MRI) and 18F-deoxyglucose positron emission tomography (PET) before and after treatment with clozapine. We investigated the association between changes in positive, disorganized, and negative schizophrenic syndromes with clozapine treatment and a set of cerebral variables that included total intracranial volume (ICV); hippocampal, dorsolateral prefrontal (DLPF) and temporal gray-matter volume and metabolism; and metabolic activity of the thalamus, pallidum/putamen, and caudate head. Improvement in positive symptoms with clozapine was directly related to temporal gray-matter volume, whereas improvement of disorganization symptoms was inversely related to ICV and hippocampal volume. Patients with high baseline DLPF cortical volume and metabolic activity were more likely to experience improvement in their negative symptoms. We conclude that clinical improvement with clozapine may be related with the anatomy and metabolic activity of specific brain areas, with the structural integrity of the DLPF and temporal regions showing the maximum predictive capacity.

[1]  B. Bogerts,et al.  The temporolimbic system theory of positive schizophrenic symptoms. , 1997, Schizophrenia bulletin.

[2]  J. Ashburner,et al.  Multimodal Image Coregistration and Partitioning—A Unified Framework , 1997, NeuroImage.

[3]  Karl J. Friston,et al.  Voxel-Based Morphometry—The Methods , 2000, NeuroImage.

[4]  L. DeLisi,et al.  Positron emission tomography studies of basal ganglia and somatosensory cortex neuroleptic drug effects: Differences between normal controls and schizophrenic patients , 1987, Biological Psychiatry.

[5]  N C Andreasen,et al.  Automatic atlas-based volume estimation of human brain regions from MR images. , 1996, Journal of computer assisted tomography.

[6]  J. Brodie,et al.  Negative symptoms and hypofrontality in chronic schizophrenia. , 1992, Archives of general psychiatry.

[7]  R. Murray,et al.  Reduction of cortical volume in schizophrenia on magnetic resonance imaging , 1993, Psychological Medicine.

[8]  R I Grossman,et al.  Frontal and temporal lobe brain volumes in schizophrenia. Relationship to symptoms and clinical subtype. , 1995, Archives of general psychiatry.

[9]  R E Litman,et al.  The brain metabolic patterns of clozapine- and fluphenazine-treated patients with schizophrenia during a continuous performance task. , 1997, Archives of general psychiatry.

[10]  J. Knoll,et al.  Heterogeneity of the psychoses: is there a neurodegenerative psychosis? , 1998, Schizophrenia bulletin.

[11]  Jeffrey A Lieberman,et al.  Is schizophrenia a neurodegenerative disorder? a clinical and neurobiological perspective , 1999, Biological Psychiatry.

[12]  H. Fukuzako,et al.  Phosphorus magnetic resonance spectroscopy in schizophrenia: Correlation between membrane phospholipid metabolism in the temporal lobe and positive symptoms , 1996, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[13]  E. Lambe,et al.  MRI correlates of treatment response in first episode psychosis , 1998, Schizophrenia Research.

[14]  Y. Kawasaki,et al.  Left Hypofrontality Correlates with Blunted Affect in Schizophrenia , 1992, The Japanese journal of psychiatry and neurology.

[15]  L. Friedman,et al.  Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia , 1991, Biological Psychiatry.

[16]  Niels G. Waller.  The Scale for the Assessment of Negative Symptoms , 1995 .

[17]  Karl J. Friston,et al.  Patterns of Cerebral Blood Flow in Schizophrenia , 1992, British Journal of Psychiatry.

[18]  S. Potkin,et al.  Clozapine effects on glucose metabolic rate in striatum and frontal cortex. , 1994, The Journal of clinical psychiatry.

[19]  V. M. Rodríguez,et al.  SPECT study of regional cerebral perfusion in neuroleptic-resistant schizophrenic patients who responded or did not respond to clozapine. , 1996 .

[20]  V. M. Rodríguez,et al.  Fronto-striato-thalamic perfusion and clozapine response in treatment-refractory schizophrenic patients. A99mTc-HMPAO study , 1997, Psychiatry Research: Neuroimaging.

[21]  P. Gloor.  The Temporal Lobe and Limbic System , 1997 .

[22]  N C Andreasen,et al.  Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. , 1992, Archives of general psychiatry.

[23]  T. Inubushi,et al.  Correlations of phosphomonoesters measured by phosphorus-31 magnetic resonance spectroscopy in the frontal lobes and negative symptoms in schizophrenia , 1994, Psychiatry Research: Neuroimaging.

[24]  R. Mailman,et al.  Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation , 1998, Brain Research.

[25]  R Kikinis,et al.  Prefrontal cortex and schizophrenia. A quantitative magnetic resonance imaging study. , 1995, Archives of general psychiatry.

[26]  Andrés Santos,et al.  Multimodality image quantification using the Talairach grid , 2001, SPIE Medical Imaging.

[27]  Jerome Engel,et al.  The Temporal Lobe and Limbic System , 1998 .

[28]  J. Olney,et al.  Glutamate receptor dysfunction and schizophrenia. , 1995, Archives of general psychiatry.

[29]  J S Fowler,et al.  Effects of haloperidol challenge on regional cerebral glucose utilization in normal human subjects. , 1994, The American journal of psychiatry.

[30]  C. Tamminga.  Glutamatergic aspects of schizophrenia , 1999, British Journal of Psychiatry.

[31]  M. Buchsbaum,et al.  Structural and functional correlates of subsyndromes in chronic schizophrenia. , 1995, Psychopathology.

[32]  D. Mathalon,et al.  Association between regional brain volumes and clozapine response in schizophrenia , 1998, Biological Psychiatry.

[33]  Karl J. Friston,et al.  Grey matter correlates of syndromes in schizophrenia , 1997, British Journal of Psychiatry.

[34]  M S Buchsbaum,et al.  Effects of clozapine and thiothixene on glucose metabolic rate in schizophrenia. , 1992, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[35]  H. Wright,et al.  Phencyclidine-induced psychosis. , 1980, Southern medical journal.

[36]  G. Brown,et al.  Effect of neuroleptics on altered cerebral glucose metabolism in schizophrenia. , 1988, Archives of general psychiatry.

[37]  P. Rakic,et al.  Modulation of neuronal migration by NMDA receptors. , 1993, Science.

[38]  R Kikinis,et al.  Superior temporal gyrus volume abnormalities and thought disorder in left-handed schizophrenic men. , 1999, The American journal of psychiatry.

[39]  J. Lieberman,et al.  Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. , 1994, The American journal of psychiatry.

[40]  K O Lim,et al.  Brain gray and white matter volume loss accelerates with aging in chronic alcoholics: a quantitative MRI study. , 1992, Alcoholism, clinical and experimental research.

[41]  Karl J. Friston,et al.  Human Brain Function , 1997 .

[42]  M S Buchsbaum,et al.  Striatal metabolic rate and clinical response to neuroleptics in schizophrenia. , 1992, Archives of general psychiatry.

[43]  J. Mazziotta,et al.  MRI‐PET Registration with Automated Algorithm , 1993, Journal of computer assisted tomography.